• Continuation of NANORAY-312, a global phase III registration study in patients with locally advanced squamous cell carcinoma of the head and neck (LA-HNSCC), already initiated in Europe, with the activation of the first clinical site in United States expected in the third quarter of 2022.
• Submission of a protocol for a potential pivotal phase III study of NBTXR3 in combination with anti-PD-1 scheduled for the first quarter of 2023, following receipt of preliminary comments from the FDA.
• Cash of €70.6 million as of March 31, 2022.
• Extension of the Company’s financial visibility until the fourth quarter of 2023 with the prioritization of research and development programs in order to reduce operating expenses and the establishment of a flexible equity financing line which could be used if the Company deems it necessary.
• Exploration by the Company of a project to reschedule its debt, with a view to further increasing its financial visibility.